Cardiovascular (CV) disease is the leading cause of death in the United States. 1 It has been shown that about 50% of cardiac events occurred in asymptomatic individuals. 2 This emphasizes the significance of risk stratifications among asymptomatic patients, beyond the conventional CV risk factors. Left ventricular hypertrophy (LVH) as determined by echocardiography is associated with increased CV risk in hypertensive patients. 3, 4 Coronary artery calcification (CAC) score is one marker of coronary atherosclerosis. 5 It has been found to be a powerful predictor of CV events among asymptomatic individuals, with an incremental value beyond traditional CV risk factors. 6 Moreover, several studies have found that the presence and degree of CAC are correlated with future cardiac events and all-cause mortality. 6-10 Several studies showed that LVH is associated with CAC. [11] [12] [13] [14] This suggests that concentric LVH is an independent risk factor for subclinical atherosclerosis. It is possible that LVH reflects target organ damage from hypertension, thus providing a noninvasive barometer of the extent of atherosclerotic heart disease.
METHODS

Patient selection
The study group was a subgroup of 544 subjects who enrolled in 1995 to the calcification arm of the INSIGHT (International Nifedipine Study Intervention as Goal for Hypertension Therapy) that compared the effect of the calcium antagonist Nifedipine versus a diuretic on the progression of coronary calcification during 3 years of follow-up. 18, 19 Hypertensive patients with at least one additional CV risk factor but without symptoms or established CV disease at baseline, males over the age of 40 years, and females over the age of 50 years, who had long-term follow up, were included in the present study. Additional CV risk factors included: smoking (active smoking or cessation of smoking less than a year before the initiation of the study), hypercholesterolemia (defined as total cholesterol of ≥250 mg/ dl or when the patient reported using cholesterol lowering drugs), diabetes mellitus type 1 or 2 (defined when a history of diabetes mellitus was reported or the patient used insulin or oral hypoglycemic medications), history of CV disease in the family (defined as first degree relatives), and proteinuria (≥0.5 g in a 24-hour urine collection). Ninetyeight patients with symptomatic coronary heart disease and 23 patients with symptomatic peripheral vascular disease at baseline were excluded from the study. Those who did not undergo an echocardiogram at baseline or were lost of followed were also excluded from the study. Eventually, a total of 252 patients were included in this study ( Figure 1 ).
Each subject was evaluated clinically at baseline, and a detailed medical history was taken and standard physical examination performed. The following variables were recorded: age, height, weight, blood pressure, comorbidities, smoking history, and routine laboratory test results. Estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation. 20 Each patient underwent coronary computed tomography (CT) and echocardiogram at baseline.
Coronary CT
All CT scans were performed in a single center and analyzed by a single experienced physician. Scans were performed using a dual-detector spiral CT machine without electrocardiographic gating and without contrast injection. Scanning protocol and CAC measurements were done according to a previously published protocol using the modified Agaston method. 21, 22 The reproducibility of calcification scoring by this method is high, with an intraclass correlation coefficient of 0.99 and of 0.94 for interobserver agreement. 21 A total calcium score >0 was considered positive for the presence of CAC.
Echocardiogram
Echocardiographic studies were performed at rest with the patient at a steady state in the left lateral position, using commercially available Hewlett Packard 1000 or newer systems with 2.5 MHz transducers as previously described. 23 Left ventricular (LV) end-diastolic and end-systolic diameters, interventricular septal, and LV posterior wall thickness, and left atrial dimension, were measured from 2 dimensionally directed M-mode echocardiogram according to the American Society of Echocardiography's guidelines using a leading edge to leading edge method. 24 Left ventricular mass (LVM) was calculated by Devereux's formula, considering the diastolic measurements of left ventricular internal diameter, interventricular septal thickness, and posterior wall thickness. 25 LVM index was calculated by dividing the LVM by the body surface area. LVH was diagnosed when interventricular septal and/or posterior wall thickness were at least 12 mm, or when LVM index was >110 g/m 2 in women or 134 g/m 2 in men.
Cardiovascular events
Subjects' files were reviewed through 2012. Subjects who were lost to follow-up were contacted, and the end points were assessed by a telephone interview using a standard questioner. Data on mortality and cause of death were available for all participants and derived from the registry of the Ministry of Internal Affairs. Only the first CV event was counted. Death from CV cause included sudden death, death from coronary heart disease, congestive heart failure, and cerebrovascular disease. CV event included acute myocardial infarction, hospitalization for unstable angina or coronary catheterization that resulted in angioplasty or coronary artery bypass surgery, stroke, or transient ischemic attack. The entire study was approved by the institutional Helsinki committee.
Statistical analysis
Data were analyzed with SPSS software version 21.0 (SPSS Headquarters, Chicago, IL). Clinical characteristics of study subjects were compared between patients with and without CAC and according to the presence or absence of LVH, and between patients who had a CV event and those who did not. Data were presented as mean and SD for continuous variables and as frequency and percentage for categorical variables. The significance levels where set to 0.05. Clinical characteristics of study subjects were compared by chisquare tests for categorical variables and independent t-tests or analysis of variance test for continuous variables. The relation between CV events and the continuous variables was tested with a t-test for independent samples and with an X 2 test for the categorical variables. Time to event was calculated as the time, in days, from the initial check up until the first CV event or until the last follow up. The incidence of CV events was analyzed according to the presence or absence of CAC and the existence of LVH.
Hazard ratios (HRs) and 95% confidence intervals (CI) for an incident of CV event were estimated using cox proportional hazard model adjusting for potential cofounders. Conventional risk factors were selected for the model based on previous studies and an association with CV events in the univariate analysis. An enter selection analysis was performed to demonstrate adjusted statistical significance in the presence of other major significant variables. The KaplanMeier procedure compared time to event between those with CAC and without CAC, by those with or without LVH (4 groups).
RESULTS
Patients' characteristics
The study population consisted of 252 subjects (54% men) with a mean age of 64.7 ± 5.5 years. One hundred and fifty-nine patients (63%) had CAC and 72 patients (28.5%) had LVH. Among those without CAC, 28 patients (30.1%) had LVH and among those with CAC 44 (27.7%) had LVH. Subjects with CAC were older (P < 0.001) and more likely to be men, and had lower eGFR (Table 1) . Other baseline characteristics, including echocardiographic parameters, were similar between patients with and without CAC ( Table 2) .
Cardiovascular events
During the long-term follow up (mean 13.3 ± 2.6 years) 89 patients had a first CV event. CV death-27, acute myocardial infarction-16, unstable angina resulted in revascularization-24, and stroke/transient ischemic attack -22. Those who experienced a CV event were more likely to be men, and to have proteinuria. They also had lower serum high-density lipoprotein cholesterol levels, and lower eGFR than those who did not experience CV event (Table 3) .
Patients who experienced CV event were more likely to have CAC and had higher LVM index and were more likely to have LVH (Table 3) .
The event rate was higher in those with CAC (43.4%) than in those without CAC (21.5%) (P < 0.001). Similarly, the event rate was higher in those with LVH (44.4%) than in those without LVH (31.6%) (P < 0.01).
We found a significant interaction between CAC and LVH with an hazard ratio of 2.85 (95% CI, 1.62-5.001) (P ≤ 0.001) adjusted for age, gender, hypercholesterolemia, high-density lipoprotein cholesterol, eGFR, and proteinuria. Among those without CAC, the rate of CV events was the same in those with and without LVH, whereas in those with CAC the rate of CV events was almost double in those with LVH than in those without LVH (Figure 2) .
LVH affected long-term CV events only in subjects with CAC. Compared to those who have no CAC and no LVH, the unadjusted hazard ratio was 0.79 (95% CI, 0.29-2.17) in those without CAC and with LVH and 3.57 (95% CI, 1.90-6.72) in those with CAC and LVH. The effect of LVH remained significant only in patients with CAC even after adjustment for age, gender, hypercholesterolemia, proteinuria, and eGFR, with an adjusted hazard ratio of 4.4 (95% CI, 2.02-9.56) ( Table 4) .
The 15 years age-and gender-adjusted survival to first CV event curve by the presence or absence of CAC in those with and without LVH is presented in Figure 3 (P < 0.01). Those with CAC and LVH had the worst outcome.
DISCUSSION
In the present study, we showed that the presence of CAC and LVH are independently associated with long-term CV events in asymptomatic hypertensive adults. The main finding of this study is that in patients without CAC the presence of LVH is not associated with increased CV events, whereas in patients with CAC the presence of LVH almost doubles the risk of CV events. This is the first study that showed the predictive value of CAC in asymptomatic hypertensive patients with echocardiographic LVH.
LVH secondary to arterial hypertension is a result of the response of myocyte and nonmyocyte components to mechanical and neurohumoral stimuli. 25 Although the mechanisms underlying this process remain incompletely understood, available evidence from the last 2 decades indicates that chronic hemodynamic overload has a driving role in activating LV myocardial growth; in turn, nonhemodynamic variables (that is, genetic, ethnic, environmental, and hormonal factors) modulate the extent and type of the hypertrophic response in the molecular level. 26 As such, LVH in hypertensive patients may be regarded as a powerful, independent biomarker reflecting the impact of pressure overload as well as of several risk factors on the heart, and is recognized as an intermediate marker of hypertensionrelated target organ damage, and a strong predictor of CV events. 27 Several studies have shown that LVH is a significant risk factor for CV morbidity and mortality. 3, 28 We also found in the entire study population that LVH was associated with increased CV events. The significant association between LVH and CV events has several possible mechanisms. LVH increases myocardial oxygen consumption while reducing coronary blood-flow reserve. This supply-demand mismatch may predispose patients to myocardial ischemia, and sudden cardiac death. There is evidence that coronary reserve is impaired in hypertrophied ventricles. 29 In patients with LVH, coronary blood supply may be impaired by coronary atherosclerosis. 30 CAC is a marker of atherosclerosis and is associated with increased CV risk and total mortality. 31, 32 We have previously Heart rate (beats/min) 73 ± 9 73 ± 10 74 ± 9 73 ± 10 0.917
Associated disease
Smoking, n (%) 14 (22) 6 (21) 25 (22) 9 (21) 0.999
Positive family history, n (%)
8 (12) 1 (4) 12 (10) 6 (14) 0.558
Diabetes mellitus, n (%) 22 (34) 10 (36) 40 (35) 17 (39) 0.962
26 (40) 14 (50) 46 (40) 16 (36) 0.710
Proteinuria, n (%) 2 (3) 2 (7) 7 (6) 7 (16) shown in normotensive healthy subjects that the presence of CAC can predict the development of hypertension. 33 Several studies have emphasized the additional value of CAC in CV risk stratification, particularly in subjects with moderate CV risk. 15, 34, 35 Recent long-term studies showed that lack of CAC is associated with a favorable prognosis. 16, 17 We have shown in diabetic hypertensive patients that lack of CAC is associated with low CV risk. 36 In the present study, we also showed that there is an interaction between CAC and LVH. This interaction is important because in patients without CAC the existence of LVH is not associated with increased CV events. CAC score can be acquired from chest CT that is done for various indications. The absence of CAC can identify hypertensive patients with LVH who are at low CV risk. In patients with LVH, impaired coronary blood flow is one of the reasons for increased cardiac events. Lack of CAC (21) 34 (21) 20 (22) 0.776
Positive family history, n (%) 27 (11) 18 (11) indicates "less" atherosclerosis. Thus, it is possible that in the absence of CAC coronary reserve is intact even in the presence of LVH. Some previous studies found an association between CAC and LVH. [12] [13] [14] In our study, we did not find more LVH in patients with CAC. Our findings are in accordance with those of Nielsen et al. who recently did not find correlation between LVH and CAC. 37 It is possible that the mechanisms which are responsible for the development of CAC and LVH are different. CAC is a marker of atherosclerosis and LVH is an index of pressure load. We believe that CAC is a better integrative marker of atherosclerosis and CV risk than LVH. It seems that CAC is an important additional parameter for assessment of CV risk. Yet, it is expensive and not widely available. A recent study by Roberts et al. suggests that it may be cost effective to include CAC in the assessment of CV risk. 38 While cost effectiveness of a dedicated CAC scan should be further proven, it is suggested that radiologists will add a CAC estimation or score in patients who undergo a chest CT for other indications as recently addressed by Hecht et al. 39 CAC score can be acquired in both gated and nongated acquisition scans and the additional burden of adding CAC score to the report may be well justified, due its significant predictive role in an asymptomatic population. In the present study, we showed that the presence of CAC determined the risk of patients with LVH and therefore even the identification of CAC without quantification may be worthwhile. Our study has several limitations. First, the study group is relatively small, particularly the subgroup of patients without CAC and with LVH, but we had a very long-term follow up with enough CV events to identify the interaction between CAC and LVH. Secondly, the echocardiogram used in our study was a 2 dimensional one. Today, the 3-dimensional echocardiogram is much more available than in the past, and has shown to have superior correlation with clinical outcomes. However, most of the studies which related LVH to CV events were done with 2-dimensional echocardiography.
In conclusion, we have demonstrated the first time that LVH is a significant risk factor for CV events only in hypertensive patients with CAC. We therefore suggest assessing the presence of CAC in every hypertensive patient who underwent chest CT. 
